Krystal Biotech, Inc.
HealthcareNASDAQ:KRYS · NASDAQ Global Market
-$3.58 today
Vol 0.29M · Avg 0.28M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
16.8%
avg -45.5%
ROIC
13.1%
avg -12.6%
ROA
15.4%
avg -10.8%
Analysis
ROE is currently the strongest return metric at 16.8% versus its period average of -45.5%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Krish S. Krishnan | Founder, Chairman, President & Chief Executive Officer | $1.66M | — | 61 | $1.40M | 4.76% |
Suma Krishnan | Founder, President of R&D and Director | $1.11M | — | 61 | $1.40M | 4.76% |
Kathryn A. Romano | Executive Vice President & Chief Accounting Officer | $674,756.00 | — | 44 | $22,366.00 | 0.08% |
John Thomas | EVP, General Counsel & Corporate Secretary | — | — | 52 | $0.00 | <0.01% |
John Karakkal | Vice President of North American Sales & Marketing | — | — | — | $0.00 | <0.01% |
Josh Suskin | Senior Director & Head of US Human Resources | — | — | — | — | — |
Laurent Goux | Executive VP & Head of International | — | — | 51 | $919.00 | <0.01% |
Christine Wilson | Senior VP & Head of US Commercial | — | — | — | — | — |
David Chien | Senior Vice President of Clinical Development | — | — | — | $125,000.00 | 0.42% |
Stephane Paquette | Senior Vice President of Corporate Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
137
$93.77M
Net Sentiment
$93.77M
Net selling
Most Active
Krishnan Suma
52 transactions
1–10 of 137
Analysis
Insiders reported 0 buys worth $0.00 and 137 sells worth $93.77M over the last 12 months. That adds up to net selling of $93.77M. Krishnan Suma was the most active insider with 52 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.50B
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.58B
Metsera, Inc.
MTSR
$7.43B
Alkermes plc
NASDAQ:ALKS
$7.38B
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
$7.06B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.85B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.23B
Teleflex Incorporated
NYSE:TFX
$5.78B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.80B
Who manages KRYS?
Krystal Biotech, Inc. (KRYS) lists 10 active executives. The top listed executive is Kathryn A. Romano, Executive Vice President & Chief Accounting Officer.
Are KRYS insiders buying or selling?
Recent insider activity shows net selling of $90.39M.
Explore More
Continue the stock analysis
Jump to another research area for this company.